Thrombotic Thrombocytopenic Purpura-Then and Now

ABSTRACT

Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and formation of microthrombi in several organs. The disease may manifest once in a lifetime or may relapse after complete recovery of the initial episode; in these recurrent cases, death or neurological sequelae are common final outcomes. Accumulation of unusually large (UL) von Willebrand factor (VWF) multimers was described in the plasma of patients with TTP. Such ULVWF multimers are synthesized in endothelial cells and megakaryocytes and are secreted into the blood upon stimulation. However, in healthy individuals ULVWF multimers do not normally circulate because they are rapidly reduced into smaller multimers soon after their secretion due to cleavage by a plasma metalloprotease, ADAMTS13. Deficiency of ADAMTS13 has been reported consistently in patients with TTP. Such defect may be constitutive, due to homozygous or double heterozygous mutations in the corresponding gene, or acquired, due to the presence of circulating inhibitory antibodies. It follows that in TTP patients, the absent or severely depressed plasma ADAMTS13 activity limits the cleavage of ULVWF multimers, which remain anchored to the endothelial cells in long strings. Particularly under conditions of high shear stress, the multimers may promote the adhesion of circulating platelets, initiating thrombus formation. The clinical implications of these findings to the diagnosis and treatment of TTP are discussed.

KEYWORDS

Thrombotic thrombocytopenic purpura - von Willebrand factor - ADAMTS13 - endothelial damage - hemolytic uremic syndrome

REFERENCES

• 1 Moschcowitz E. Acute febrile pleiochromic anemia with hyaline thrombosis of a terminal arterioles and capillaries: an undescribed disease.  Arch Intern Med. 1925;  36 89-93
• 2 Kennedy S S, Zacharski L R, Beck J R. Thrombotic thrombocytopenic purpura: analysis of 48 unselected cases.  Semin Thromb Hemost. 1980;  6 341-349
• 3 Amorosi E L, Ultmann J E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.  Medicine. 1966;  45 139-159
• 4 Cuttner J. Thrombotic thrombocytopenic purpura: a ten-year experience.  Blood. 1980;  56 302-306
• 5 Bukowski R M. Thrombotic thrombocytopenic purpura: a review. In: Spaet TH Progress in Hemostasis and Thrombosis. New York; Grune & Stratton 1982: 287-337
• 6 Ruggenenti P, Remuzzi G. Thrombotic thrombocytopenic purpura and related disorders.  Hematol Oncol Clin North Am. 1990;  4 219-241
• 7 Silverstein A. Thrombotic thrombocytopenic purpura: the initial neurologic manifestations.  Arch Neurol. 1968;  18 358-362
• 8 Percival S PB. Ocular findings in thrombotic thrombocytopenic purpura (Moschowitz's disease).  Br J Ophthalmol. 1970;  54 73-78
• 9 Chen Y C, McLeod B, Hall E R, Wu K K. Accelerated prostacyclin degradation in thrombotic thrombocytopenic purpura.  Lancet. 1981;  2 267-269
• 10 Cuttner J. Chronic thrombotic thrombocytopenic purpura: report of a case with five relapses and review of the literature.  Mt Sinai J Med. 1978;  45 418-425
• 11 Meacham G C, Orbison J L, Heinle R W, Steele H J, Schaefer J A. Thrombotic thrombocytopenic purpura a disseminated disease of arterioles.  Blood. 1952;  6 706-719
• 12 Fuchs W E, George J N, Dotin L N, Sears D A. Thrombotic thrombocytopenic purpura-occurrence two years apart during late pregnancy in two sisters.  JAMA. 1976;  235 2126-2127
• 13 Hellman R M, Jackson D V, Buss D H. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in HLA-identical siblings.  Ann Intern Med. 1980;  93 283-284
• 14 Altschule M D. A rare type of acute thrombocytopenic purpura: widespread formation of platelet thrombi in capillaries.  N Engl J Med. 1942;  227 477-479
• 15 Remuzzi G, Ruggenenti P, Bertani T. Thrombotic microangiopathies. In: Tisher CC, Brenner BM Renal Pathology. With Clinical and Functional Correlations. Philadelphia, PA; J.B. Lippincott 1994: 1154-1184
• 16 Ruiz-Torres M P, Casiraghi F, Galbusera M et al.. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.  Thromb Haemost. 2005;  93 443-452
• 17 Mitra D, Jaffe E A, Weksler B, Hajjar K A, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.  Blood. 1997;  89 1224-1234
• 18 Neild G H. Mechanisms and models of endothelial injury. In: Bertani T, Remuzzi G Glomerular Injury 300 Years After Morgagni. Milan, Italy; Wichtig 1983: 139-162
• 19 Kniker W T, Cochrane C G. Pathogenetic factors in vascular lesions of experimental serum sickness.  J Exp Med. 1965;  122 83-98
• 20 Kniker W T, Cochrane C G. The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodinamic forces.  J Exp Med. 1968;  127 119-136
• 21 Lowenhaupt R, Nathan P. The participation of platelets in the rejection of dog kidney allotransplants: hematologic and electron microscopic studies.  Transplant Proc. 1969;  1 305-310
• 22 Sharma H M, Moore S, Merrick H W, Smith M R. Platelet in early hyperacute allograft rejection in kidneys and their modification by sulfinpyrazone (Anturan) therapy: an experimental study.  Am J Pathol. 1972;  66 445-460
• 23 Wall R T, Harker L A. The endothelium and thrombosis.  Annu Rev Med. 1980;  31 361-371
• 24 Foster P A, Anderson J C. Effects of plasma from patients with thrombotic thrombocytopenic purpura (TTP) on cultured human endothelial cells (abst).  Blood. 1979;  54 240a
• 25 Bennett C L, Weinberg P D, Rozenberg-Ben-Dror K, Yarnold P R, Kwaan H C, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases.  Ann Intern Med. 1998;  128 541-544
• 26 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342 1773-1777
• 27 Ferretti G, Petti M C, Carlini P et al.. Zoledronic acid-associated thrombotic thrombocytopenic purpura.  Ann Oncol. 2004;  15 1847-1848
• 28 Sundram F, Roberts P, Kennedy B, Pavord S. Thrombotic thrombocytopenic purpura associated with statin treatment.  Postgrad Med J. 2004;  80 551-552
• 29 Neame P B. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP).  Semin Thromb Hemost. 1980;  6 416-429
• 30 Leaf A N, Laubenstein L J, Raphael B, Hochster H, Baez L, Karpatkin S. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-1) infection.  Ann Intern Med. 1988;  109 194-197
• 31 Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura.  Eur J Haematol. 1996;  56 191-207
• 32 Lian E CY, Harkness D R, Byrnes J J, Wallach H, Nunez R. Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma.  Blood. 1979;  53 333-338
• 33 Lian E CY, Siddiqui F A, Chen S H, Feng L M. Platelet-agglutinating/aggregating proteins from the plasma of patients with thrombotic thrombocytopenic purpura. In: Kaplan BS, Trompeter RS, Moake JL HUS and TTP. New York; Marcel Dekker 1992: 473-481
• 34 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 35 Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of constituent subunit.  J Clin Invest. 1991;  88 774-782
• 36 Moake J L, McPherson P D. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  Am J Med. 1989;  87 9N-15N
• 37 Moake J L. Moschcowitz, multimers, and metalloprotease.  N Engl J Med. 1998;  339 1629-1631
• 38 Moake J L. Hemolytic-uremic syndrome: basic science.  Lancet. 1994;  343 393-397
• 39 Tsai H M, Sussman I I, Nagel R L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma.  Blood. 1994;  83 2171-2179
• 40 Furlan M, Robles R, Galbusera M et al.. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 41 Tsai H M, Lia E CY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 42 Soejima K, Nakagaki T. Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies.  Semin Hematol. 2005;  42 56-62
• 43 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 44 Bork P, Beckmann G. The CUB domain. A widespread module in developmentally regulated proteins.  J Mol Biol. 1993;  231 539-545
• 45 Bornstein P. Thrombospondin as matricellular modulators of cell function.  J Clin Invest. 2001;  107 929-934
• 46 Ruoslahti E, Pierschbacher M D. Arg-Gly-Asp: a versatile cell recognition signal.  Cell. 1986;  44 517-518
• 47 Upshaw J D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia.  N Engl J Med. 1978;  298 1350-1352
• 48 Moake J L. Thrombotic microangiopathies.  N Engl J Med. 2002;  347 589-600
• 49 Veyradier A, Obert B, Houiller A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98 1765-1772
• 50 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood. 1998;  91 2839-2846
• 51 Kokame K, Matsumoto M, Soejima K et al.. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.  Proc Natl Acad Sci USA. 2002;  99 11902-11907
• 52 Matsumoto M, Kokame K, Soejima K et al.. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.  Blood. 2004;  103 1305-1310
• 53 Uchida T, Wada H, Mizutani M et al.. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura.  Blood. 2004;  104 2081-2083
• 54 Klaus C, Plaimauer B, Studt J D et al.. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4514-4519
• 55 Remuzzi G, Galbusera M, Noris M et al.. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and haemolytic uremic syndrome.  Blood. 2002;  100 778-785
• 56 Soejima K, Matsumoto M, Kokame K et al.. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.  Blood. 2003;  102 3232-3237
• 57 Galbusera M, Noris M, Rossi C et al.. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP.  Blood. 1999;  94 610-620
• 58 Vesely S K, George J N, Lämmle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 59 Tsai H M. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes.  J Thromb Haemost. 2003;  1 625-631
• 60 Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No.  J Thromb Haemost. 2003;  1 632-634
• 61 Noris M, Bucchioni S, Galbusera M et al.. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement.  J Am Soc Nephrol. 2005;  16 1177-1183
• 62 Dong J F, Moake J L, Nolasco L et al.. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.  Blood. 2002;  100 4033-4039
• 63 Del Conde I, Cruz M A, Zhang H, Lopez J A, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system.  J Exp Med. 2005;  201 871-879
• 64 Wright J F, Wang H, Horsnstein A et al.. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 1999;  107 546-555
• 65 Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H-M. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.  Br J Haematol. 2004;  124 787-795
• 66 Galbusera M, Moris M, Gastoldi S et al.. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.  Blood. 2005;  106 925-928